Karyopharm Therapeutics Inc (NAS:KPTI)
$ 0.93 -0.0427 (-4.39%) Market Cap: 115.89 Mil Enterprise Value: 143.75 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Karyopharm Therapeutics Inc at Jefferies Virtual London Healthcare Conference Transcript

Nov 17, 2020 / 06:45PM GMT
Release Date Price: $16.3 (+0.56%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Karyopharm team with us today. We're going to do a fireside chat to talk about Karyopharm. And with us, we've got Michael Kauffman, the CEO; Mike Mason, the CFO; and Ian Karp from Investor Relations.

So thanks, everyone, for joining us today. And maybe to start off, Michael, if you want to provide an intro to Karyopharm for those who might not be familiar with the story.

Michael G. Kauffman
Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director

Sure. Karyopharm was founded in 2009, focused on modulating nuclear export from the cell nucleus and treating diseases like cancer and other abnormalities, including autoimmune disease and certain viruses. We have our lead product, it's called XPOVIO. It's now marketed for 2 indications. It entered the clinic as selinexor, a first-in-class oral inhibitor of the nuclear export, protein

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot